Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Prikl Biokhim Mikrobiol ; 50(5): 481-9, 2014.
Article in Russian | MEDLINE | ID: mdl-25707105

ABSTRACT

Five bacterial strains with the unique ability to utilize low-molecular linear caprolactam olygomers (nylon olygomers) were isolated from soil samples contaminated with industrial wastes of epsilon-caprolactam. Based on the properties studied and also on the analysis of 16S rRNA gene nucleotide sequences, the strains BS2,BS3, BS9, BS38, and BS57 were classified to the general Arthrobacter, Brevibacterium, Microbacteriun, Gulosibacter, and Achromobacter, respectively. All of the strains also utilized 6-aminohexanoic and adipic acids, which are intermidiates of the epsilon-caprolactam catabolism. This indirectly points to the fact that degradation of olygomers in these bacteria occurs via the monomer degradation pathway. The BS9 and BS57 strains utilized only olygomers of the epsilon-caprolactam, while BS2, BS3, and BS38 also degraded epsilon-caprolactam and its homologs, enantolactam and caprylolactam, which differentiates the latter from the previously known degraders of olygomers and suggests the presence in these strains of enzymes with lactam hydrolase activity, in addition to 6-aminohexanoate-dimer hydrolase.


Subject(s)
Achromobacter/metabolism , Amidohydrolases/metabolism , Arthrobacter/metabolism , Bacterial Proteins/metabolism , Brevibacterium/metabolism , Caprolactam/metabolism , DNA, Bacterial/genetics , Achromobacter/genetics , Achromobacter/growth & development , Adipates/metabolism , Aminocaproates/metabolism , Arthrobacter/genetics , Arthrobacter/growth & development , Biodegradation, Environmental , Brevibacterium/genetics , Brevibacterium/growth & development , Humans , Industrial Waste , RNA, Ribosomal, 16S/genetics
2.
Kardiologiia ; 51(6): 60-5, 2011.
Article in Russian | MEDLINE | ID: mdl-21878073

ABSTRACT

We followed for 15 years 31 patients with mitral valve prolapse (MVP) who during follow-up regularly took orotic acid (1500 mg/day) for 3 months twice a year. We revealed peculiarities of dynamics of clinical picture, their interrelation with phenotypic manifestations of connective tissue dysplasia, changes of electrocardiogram, structure of valvular apparatus of the heart, state of vegetative homeostasis, changes of levels and 24-hour profile of arterial pressure, tone of sympathetic and parasympathetic parts of vegetative nervous system. We noted significant reduction of mean and maximal heart rate, number of episodes of tachycardia, duration of QTc intervals, incidence of paroxysmal supraventricular and ventricular extrasystoles. We fixed statistically significant lowering of maximal systolic and diastolic arterial pressure, hypertensive burden and elevated variability of systolic and diastolic arterial pressure. Data of retrospective analysis showed absolute normalization of these parameters in all studied patients. Decrease of the tone of sympathetic part of vegetative nervous system was also established. There was 2 to fold decrease of number of persons with sympathicotonia, 3 to fold increase of those with vagotonia, and 5 times increase of number of patients with equal tone of sympathetic and parasympathetic parts. Regular use of magnesium salt of orotic acid was associated with significant elevation of quality of life of patients with MVP. Clinically valuable improvement of work and social life scores was noted in 54.8%, of personal life score - in 45.2% of individuals. In half of patients with MVP index of efficacy of therapy with orotic acid was significant.


Subject(s)
Autonomic Nervous System/drug effects , Hypertension/drug therapy , Mitral Valve Prolapse/drug therapy , Mitral Valve/drug effects , Orotic Acid/analogs & derivatives , Ventricular Premature Complexes/drug therapy , Adult , Blood Pressure/drug effects , Drug Administration Schedule , Drug Monitoring , Echocardiography , Electrocardiography , Female , Follow-Up Studies , Heart Rate/drug effects , Humans , Hypertension/etiology , Hypertension/physiopathology , Male , Mitral Valve/abnormalities , Mitral Valve/diagnostic imaging , Mitral Valve Prolapse/complications , Mitral Valve Prolapse/congenital , Mitral Valve Prolapse/physiopathology , Orotic Acid/administration & dosage , Orotic Acid/adverse effects , Treatment Outcome , Ventricular Premature Complexes/etiology , Ventricular Premature Complexes/physiopathology
3.
Kardiologiia ; 51(1): 23-8, 2011.
Article in Russian | MEDLINE | ID: mdl-21626798

ABSTRACT

With the aim to assess prevalence of aortic stenosis (AS) and prognostic value of its detection among survivors of acute coronary syndrome (ACS) we examined 851 patients included into multicenter prospective study of risk factors of serious vascular events and death after acute coronary syndrome. The patients were enrolled into the study in stable condition on 10th day after onset of myocardial infarction (MI) or unstable angina (UA). Examination involved medical history, laboratory tests and echocardiography. Afterwards all cases of death and serious vascular events were registered. Severity of AS was specified by maximal aortic flow rate: 1st degree > 2.5, 2nd degree 3.0-4.0, 3rd degree > 4.0 m/s. AS was detected in 16 patients (1.9%). AS severity was 1st, 2nd and 3rd degree in 9, 4 and 3 patients, respectively. Patients with AS were significantly older (77.4 vs. 61.3 years, p < 0.001), more often had history of chronic heart failure (CHF) (81.3 vs. 53.2%, p = 0.021) and lowered renal function (66.7 vs. 34.0%, p < 0.041). At multifactorial analysis independent prognostic value in relation to development of serious events showed age > 75 years (OR 1,395 [1.023-1.902], p = 0.036), history of CHF (1.319 [1.015-1.713], p = 0.038), history of MI (1.692 [1.320-2.170], p < 0.001), left ventricular diastolic dimention (1.023 [1.005-1.041], p = 0.012), left atrial diameter (1.024 [1.001-1.047], p = 0.037) and presence of AS (3.211 [1.742-.,916], p < 0.001). Prevalence of preexisting AS among patients who have had MI/UA is 1.9% what is similar to data of European Heart Survey ACS-II (1.8%). Presence of AS of any severity in a survivor of ACS worsens prognosis independently of other known risk factors.


Subject(s)
Acute Coronary Syndrome , Aortic Valve Stenosis , Aortic Valve , Cardiovascular Diseases , Acute Coronary Syndrome/complications , Acute Coronary Syndrome/epidemiology , Acute Coronary Syndrome/physiopathology , Age Factors , Aged , Aortic Valve/diagnostic imaging , Aortic Valve/pathology , Aortic Valve/physiopathology , Aortic Valve Stenosis/complications , Aortic Valve Stenosis/epidemiology , Aortic Valve Stenosis/pathology , Aortic Valve Stenosis/physiopathology , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/etiology , Cardiovascular Diseases/mortality , Cardiovascular Diseases/physiopathology , Female , Heart Valve Diseases/diagnostic imaging , Heart Valve Diseases/pathology , Heart Valve Diseases/physiopathology , Humans , Male , Middle Aged , Prevalence , Prognosis , Prospective Studies , Risk Factors , Russia/epidemiology , Severity of Illness Index , Survivors/statistics & numerical data , Ultrasonography
4.
Mol Biol (Mosk) ; 44(5): 839-46, 2010.
Article in Russian | MEDLINE | ID: mdl-21090240

ABSTRACT

We investigated the association of gene IL6 G(-174)C polymorphism and gene IL10 G(-1082)A polymorphism with coronary artery disease (CAD) in the Russian population. A total of 1145 patients with CAD diagnose on the basis of clinical studies in cardiological hospitals of Moscow, St -Petersburg, Kazan, Chelyabinsk, Perm, Stavropol and Rostov-on-Don. Supervision term was 9.10 +/- 5.03 months (the maximum term 18 months). In case of gene IL10 G(-1082)A polymorphism we determined that patients with CAD diagnose and A alleles gene IL10 had unfavorable outcome more often than patients with homozygous G alleles. Survival time from end point from carrier genotype GA and AA is 11.68 +/- 0.67 months against 12.69 +/- 0.65 months from carrier phenotype GG gene IL10 (chi2 = 4.13, p = 0.042). The group studied do not differ significantly with respect to the distributions of gene IL6 G(-174)C alleles and genotypes. However in case combined group studies of gene IL10 G(-1082)A polymorphism and IL6 G(-174)C polymorphism we determined that patients with CAD diagnose and carrier genotype GG gene IL6 and genotype GA and AA gene IL10 had unfavorable outcome more often (survival time 11.01 +/- 1.24 months) than patients with genotype CC and CG gene IL6 and genotype GG gene IL10 (survival time 13.28 +/- 0.83 months) chi2 = 10.23, p = 0.017. The obtained data allows assuming the important role of the IL6 and IL10 genes which are responsible for functioning of inflammation system, in the accelerated formation of failures at the patients who had a coronary syndrome.


Subject(s)
Acute Coronary Syndrome/genetics , Acute Coronary Syndrome/mortality , Alleles , Interleukin-10/genetics , Interleukin-6/genetics , Polymorphism, Single Nucleotide , Acute Coronary Syndrome/diagnosis , Acute Coronary Syndrome/metabolism , Aged , Female , Genotype , Humans , Interleukin-10/metabolism , Interleukin-6/metabolism , Male , Middle Aged , Predictive Value of Tests
5.
Mol Biol (Mosk) ; 44(4): 613-9, 2010.
Article in Russian | MEDLINE | ID: mdl-20873219

ABSTRACT

We investigated the association of polymorphisms of genes FGB G(-455)A and PROCC(-1654)T with coronary artery disease (CAD) in the Russian population. A total of 1145 patients with CAD diagnose on the basis of clinical studies in cardiological hospitals of Moscow, St. Petersburg, Kazan, Chelyabinsk, Perm, Stavropol and Rostov-on-Don. Supervision term was 1.14 +/- +/- 0.33 years (the maximum term 3.2 years). The group studied do not differ significantly with respect to the distributions of G(-455)A alleles and genotypes. However in case of gene PROC C(-1654)T polymorphism we determined that patients with CAD diagnose and Talleles of PROC gene had unfavorable outcome more often than patients with homozygous C alleles. Survival time from end point from carrier phenotype TT and CTis 2.19 +/- 0.18 r. years against 2.46 +/- 0.16 from carrier phenotype CCgene PROC. The obtained data allows to assume the important role of the genes which are responsible for functioning of system of a hemostasis, in the accelerated formation of failures at the patients who had a coronary syndrome.


Subject(s)
Acute Coronary Syndrome/genetics , Acute Coronary Syndrome/mortality , Fibrinogen/genetics , Genetic Predisposition to Disease , Polymorphism, Single Nucleotide , Protein C/genetics , Alleles , Disease-Free Survival , Female , Genotype , Humans , Male , Middle Aged , Russia/epidemiology , Survival Rate
6.
Klin Med (Mosk) ; 86(3): 55-8, 2008.
Article in Russian | MEDLINE | ID: mdl-18441707

ABSTRACT

144 patients with idiopathic mitral valve prolapse (MVP) were examined. They were divided into groups of treatment with magnerot, and placebo (control group). Decrease of echocardiography indices of MVP was noticed in the patients who received magnerot. After therapy with alprazolam only tendency to decrease of prolapse depth was registered. Significant decrease of maximal systolic and diastolic pressure, mean diastolic pressure, hypertonic load with diastolic pressure and increased variability of systolic and diastolic pressure occurred after therapy with magnerot. Decrease of systolic and diastolic pressure was noticed after therapy with alprazolam. At Halter monitoring of patients with MVP were noticed that magnerot had greater effect than alprazolam to decrease of number of tachycardia (paroxysmal supraventricual and nonparoxysmal) episodes. Significant decrease of number of patients with sympathicotonia and, at the same time, increase of number of person with equal tonus of both vegetative nervous systems were registered after therapy with magnerot (by 9 times) and with alprazolam (by 4.5 times).


Subject(s)
Alprazolam/pharmacology , Alprazolam/therapeutic use , GABA Modulators/pharmacology , GABA Modulators/therapeutic use , Gluconates/therapeutic use , Mitral Valve Prolapse , Drug Therapy, Combination , Female , Heart Rate/drug effects , Humans , Male , Middle Aged , Mitral Valve Prolapse/drug therapy , Mitral Valve Prolapse/physiopathology , Mitral Valve Prolapse/psychology
7.
Ter Arkh ; 77(9): 74-6, 2005.
Article in Russian | MEDLINE | ID: mdl-16281495

ABSTRACT

AIM: To examine lymphocyte ability to synthetize interferon-gamma in patients with mitral prolapse (MP). MATERIAL AND METHODS: The diagnosis of MP was made in 75 patients at echocardiography. ECG monitoring was made and the study of the ability of blood lymphocytes to produce IFN-gamma (If-g). RESULTS: The ability to produce If-g was diminished. This phenomenon is associated with chronic inflammation, autonomic disregulation of cardiac activity, depends on gender. CONCLUSION: Cytokine modulates metabolism of connective tissue in MP so If-g may participate in MP pathogenesis. Therefore, If-g and/or its inductors may prevent some MP-related complications due to its deficiency.


Subject(s)
Interferon-gamma/metabolism , Lymphocytes/immunology , Mitral Valve Prolapse/immunology , Adult , Down-Regulation , Female , Humans , Lymphocytes/metabolism , Male , Mitral Valve Prolapse/metabolism
9.
Bull Exp Biol Med ; 131(4): 389-91, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11550034

ABSTRACT

Psychological testing using Eysenck Personality Inventory and immunological testing of 75 patients with idiopathic mitral valve prolapse revealed low production of interferon-gamma by blood lymphocytes and a correlation between interferon-gamma production and patient's temperament. Low neuroticism and extroversion scores were found in patients with normal interferon-gamma production. High neuroticism score was detected in 82% patients with lowest interferon-gamma production, which refers these patients to a group at high immunological risk and prompts the use of interferon and/or its inductors in complex therapy of these patients.


Subject(s)
Extraversion, Psychological , Interferon-gamma/biosynthesis , Introversion, Psychological , Mitral Valve Prolapse/immunology , Mitral Valve Prolapse/psychology , Mood Disorders/immunology , Adult , Female , Humans , Lymphocytes/immunology , Male , Middle Aged , Mitral Valve Prolapse/blood
10.
Klin Med (Mosk) ; 79(4): 51-3, 2001.
Article in Russian | MEDLINE | ID: mdl-11496742

ABSTRACT

Effectiveness of Mono Mac was assessed in patients with ischemic heart disease (IHD) and concomitant polycythemia vera (PV). 24-h ECG-monitoring, stress-echoCG were performed in 28 patients aged 35-79 years with painless myocardial ischemia (group 1) and painful form (group 2). Mean dose of Mono Mac was 56.4 mg/day. Clinical response was achieved. Positive changes were observed in decreased number of anginal attacks and nitroglycerin tablets, ST wave depression, number of ischemic episodes, improvement of hemodynamics. It is concluded that Mono Mac has a marked clinical effect in IHD patients having associated polycythemia vera.


Subject(s)
Isosorbide Dinitrate/therapeutic use , Myocardial Ischemia/complications , Myocardial Ischemia/drug therapy , Polycythemia Vera/complications , Vasodilator Agents/therapeutic use , Adult , Aged , Female , Humans , Isosorbide Dinitrate/administration & dosage , Isosorbide Dinitrate/analogs & derivatives , Male , Middle Aged , Vasodilator Agents/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...